166 related articles for article (PubMed ID: 21626132)
1. Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease.
Moriyama T; Tsuruta Y; Kojima C; Itabashi M; Sugiura H; Takei T; Ogawa T; Uchida K; Tsuchiya K; Nitta K
Int Urol Nephrol; 2012 Jun; 44(3):841-5. PubMed ID: 21626132
[TBL] [Abstract][Full Text] [Related]
2. Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria.
Nakamura T; Sato E; Amaha M; Kawagoe Y; Maeda S; Yamagishi S
J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):122-7. PubMed ID: 21946392
[TBL] [Abstract][Full Text] [Related]
3. Aliskiren add-on therapy effectively reduces proteinuria in chronic kidney disease: an open-label prospective trial.
Wu MT; Tung SC; Hsu KT; Lee CT
J Renin Angiotensin Aldosterone Syst; 2014 Sep; 15(3):271-7. PubMed ID: 23223162
[TBL] [Abstract][Full Text] [Related]
4. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
Moniwa N; Varagic J; Ahmad S; VonCannon JL; Simington SW; Wang H; Groban L; Brosnihan KB; Nagata S; Kato J; Kitamura K; Gomez RA; Lopez ML; Ferrario CM
Hypertension; 2013 Feb; 61(2):417-24. PubMed ID: 23232645
[TBL] [Abstract][Full Text] [Related]
5. Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease.
Abe M; Suzuki H; Okada K; Maruyama N; Inoshita A; Baba S; Takashima H; Soma M
Heart Vessels; 2013 Jul; 28(4):442-52. PubMed ID: 22618635
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Hsu H; Zhang J
Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
[TBL] [Abstract][Full Text] [Related]
7. The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease.
Yanagi M; Tamura K; Fujikawa T; Wakui H; Kanaoka T; Ohsawa M; Azushima K; Maeda A; Kobori H; Umemura S
Hypertens Res; 2013 Mar; 36(3):262-9. PubMed ID: 23154587
[TBL] [Abstract][Full Text] [Related]
8. Aliskiren combined with losartan in type 2 diabetes and nephropathy.
Parving HH; Persson F; Lewis JB; Lewis EJ; Hollenberg NK;
N Engl J Med; 2008 Jun; 358(23):2433-46. PubMed ID: 18525041
[TBL] [Abstract][Full Text] [Related]
9. Olmesartan medoxomil and azelnidipine therapy in patients with hypertension and chronic kidney disease in Japan.
Saito I; Kushiro T; Zenimura N; Matsushita Y; Sagawa K; Hiramatsu K; Yamaguchi F
J Nephrol; 2012; 25(5):699-708. PubMed ID: 22020401
[TBL] [Abstract][Full Text] [Related]
10. Effective blockade of RAAS by combination of aliskiren and olmesartan improves glucose homeostasis, glomerular filtration rate along with renal variables in streptozotocin induced diabetic rats.
Gandhi S; Srinivasan BP; Akarte AS
Eur J Pharm Sci; 2012 May; 46(1-2):32-42. PubMed ID: 22349361
[TBL] [Abstract][Full Text] [Related]
11. Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria.
Abe M; Maruyama N; Suzuki H; Fujii Y; Ito M; Yoshida Y; Okada K; Soma M
Hypertens Res; 2012 Aug; 35(8):874-81. PubMed ID: 22592665
[TBL] [Abstract][Full Text] [Related]
12. Dual RAAS Blockade with Aliskiren in Patients with Severely Impaired Chronic Kidney Disease.
Rasche FM; Joel C; Ebert T; Frese T; Barinka F; Busch V; Rasche WG; Lindner TH; Schneider J; Schiekofer S
Exp Clin Endocrinol Diabetes; 2018 Jan; 126(1):39-52. PubMed ID: 28449154
[TBL] [Abstract][Full Text] [Related]
13. Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease.
Li SY; Chen YT; Yang WC; Tarng DC; Lin CC; Yang CY; Liu WS
BMC Nephrol; 2012 Aug; 13():89. PubMed ID: 22917002
[TBL] [Abstract][Full Text] [Related]
14. Greater reductions in plasma aldosterone with aliskiren in hypertensive patients with higher soluble (Pro)renin receptor level.
Bokuda K; Morimoto S; Seki Y; Yatabe M; Watanabe D; Yatabe J; Ando T; Shimizu S; Itoh H; Ichihara A
Hypertens Res; 2018 Jun; 41(6):435-443. PubMed ID: 29618841
[TBL] [Abstract][Full Text] [Related]
15. [Renin inhibition and the kidney].
Ecder T
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():28-31. PubMed ID: 20019474
[TBL] [Abstract][Full Text] [Related]
16. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
17. Impact of mineralocorticoid receptor blockade with direct renin inhibition in angiotensin II-dependent hypertensive mice.
Hashimoto A; Takeda Y; Karashima S; Kometani M; Aono D; Demura M; Higashitani T; Konishi S; Yoneda T; Takeda Y
Hypertens Res; 2020 Oct; 43(10):1099-1104. PubMed ID: 32398797
[TBL] [Abstract][Full Text] [Related]
18. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.
Sepehrdad R; Frishman WH; Stier CT; Sica DA
Cardiol Rev; 2007; 15(5):242-56. PubMed ID: 17700383
[TBL] [Abstract][Full Text] [Related]
19. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
[TBL] [Abstract][Full Text] [Related]
20. Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients?
Hollenberg NK; Fisher ND; Nussberger J; Moukarbel GV; Barkoudah E; Danser AH
J Hypertens; 2011 Dec; 29(12):2454-61. PubMed ID: 22002336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
